Clinical Trial: A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0050 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies

U.S., Oct. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07881211) titled 'A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0050 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies' on Oct. 12.

Brief Summary: The purpose of this study is to test the safety and tolerability of BG-T0050 and to identify the recommended dose and dosing schedule (including dose levels and timing) that can be taken without having serious side effects in adults with DLBCL and other aggressive B-cell malignancies

Study Start Date: Nov. 30

Study Type: INTERVENTIONAL

Condition: Diffuse Large B-Cell Lymphoma B-Cell Malignancies

Intervention: DR...